Biologic Drug Prices in Medicare Part B After Entry of Biosimilars to the Market.

ABSTRACT:

Importance

Price reductions for originator biologics with biosimilar competitors have been modest in the US. This may be due to the US reimbursement model, where clinicians or their employing medical institution receive payment based on the percentage of the cost billed, incentivizing the highest-cost product. Currently, US policymakers are debating changing this policy. However, a clear understanding of price reductions achieved by the current system is needed to inform future reform efforts.

Objective

To assess the associations of biosimilar entry with the prices of originator biologics under Medicare Part B reimbursement.

Design, setting, and participants

This cohort study used bayesian structural time series models to analyze Medicare Part B Drug average sales pri

SUBMITTER: Abdelaziz A 

PROVIDER: S-EPMC12606378 | biostudies-literature | 2025 Nov

REPOSITORIES: biostudies-literature